Back to Search
ROXANA MEHRAN
Student in an Organized Health Care Education/Training Program
NPI: 1568048528Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Clinical Trials (2)
2
Linked Trials
1
Recruiting
1
With Results
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
NCT06909565RECRUITINGPHASE4STUDY_CHAIR
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
NCT02270242COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
Characterizing high-risk enrollment criteria and impact on clinical outcomes in a large randomized clinical trial: Insights from the TWILIGHT trial.
PMID 39889917·Am Heart J·2025
3-trial
Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry.
PMID 38972336·Am Heart J·2025
4-observational
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
PMID 38458371·Am Heart J·2024
2-rct
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
PMID 37806185·Am J Cardiol·2023
2-rct
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.
PMID 37587580·J Am Coll Cardiol·2023
3-trial
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.
PMID 37094668·Am Heart J·2023
8-other
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.
PMID 36649694·Eur Heart J Cardiovasc Pharmacother·2023
2-rct
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
PMID 35317615·Circ Cardiovasc Interv·2022
2-rct
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.
PMID 35033468·JACC Cardiovasc Interv·2022
2-rct
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
PMID 33991416·JAMA Cardiol·2021
4-observational
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
PMID 33085967·Eur Heart J·2020
2-rct
Ticagrelor With or Without Aspirin After Complex PCI.
PMID 32240761·J Am Coll Cardiol·2020
4-observational
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
PMID 32240760·J Am Coll Cardiol·2020
4-observational
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
PMID 31556978·N Engl J Med·2019
4-observational
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
PMID 31020929·J Am Heart Assoc·2019
4-observational
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
PMID 24177257·JAMA·2013
4-observational
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
PMID 22789884·J Am Coll Cardiol·2012
4-observational
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
PMID 22595163·JACC Cardiovasc Imaging·2012
8-other
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
PMID 22438530·Circulation·2012
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 300 COMMUNITY DR
MANHASSET, NY 11030 - Phone
- (516) 562-0100
Quick Facts
- NPI
- 1568048528
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile